Opus Genetics Statistics
Total Valuation
Opus Genetics has a market cap or net worth of $156.55 million. The enterprise value is $127.49 million.
Important Dates
The last earnings date was Wednesday, November 12, 2025, before market open.
| Earnings Date | Nov 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Opus Genetics has 68.96 million shares outstanding. The number of shares has increased by 99.64% in one year.
| Current Share Class | 68.96M |
| Shares Outstanding | 68.96M |
| Shares Change (YoY) | +99.64% |
| Shares Change (QoQ) | +11.46% |
| Owned by Insiders (%) | 14.59% |
| Owned by Institutions (%) | 35.12% |
| Float | 37.88M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.57 |
| Forward PS | 9.17 |
| PB Ratio | 24.12 |
| P/TBV Ratio | 26.35 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 8.71 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.23, with a Debt / Equity ratio of 0.18.
| Current Ratio | 1.23 |
| Quick Ratio | 1.21 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -546.69 |
Financial Efficiency
Return on equity (ROE) is -338.75% and return on invested capital (ROIC) is -112.42%.
| Return on Equity (ROE) | -338.75% |
| Return on Assets (ROA) | -60.73% |
| Return on Invested Capital (ROIC) | -112.42% |
| Return on Capital Employed (ROCE) | -528.43% |
| Revenue Per Employee | $812,944 |
| Profits Per Employee | -$3.79M |
| Employee Count | 18 |
| Asset Turnover | 0.38 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +89.17% in the last 52 weeks. The beta is 0.42, so Opus Genetics's price volatility has been lower than the market average.
| Beta (5Y) | 0.42 |
| 52-Week Price Change | +89.17% |
| 50-Day Moving Average | 1.98 |
| 200-Day Moving Average | 1.29 |
| Relative Strength Index (RSI) | 64.56 |
| Average Volume (20 Days) | 409,243 |
Short Selling Information
The latest short interest is 386,397, so 0.56% of the outstanding shares have been sold short.
| Short Interest | 386,397 |
| Short Previous Month | 499,215 |
| Short % of Shares Out | 0.56% |
| Short % of Float | 1.02% |
| Short Ratio (days to cover) | 0.73 |
Income Statement
In the last 12 months, Opus Genetics had revenue of $14.63 million and -$68.20 million in losses. Loss per share was -$1.37.
| Revenue | 14.63M |
| Gross Profit | -12.79M |
| Operating Income | -37.18M |
| Pretax Income | -68.20M |
| Net Income | -68.20M |
| EBITDA | -37.13M |
| EBIT | -37.18M |
| Loss Per Share | -$1.37 |
Full Income StatementBalance Sheet
The company has $30.82 million in cash and $1.07 million in debt, giving a net cash position of $29.75 million or $0.43 per share.
| Cash & Cash Equivalents | 30.82M |
| Total Debt | 1.07M |
| Net Cash | 29.75M |
| Net Cash Per Share | $0.43 |
| Equity (Book Value) | 5.97M |
| Book Value Per Share | 0.09 |
| Working Capital | 6.82M |
Full Balance SheetCash Flow
| Operating Cash Flow | -32.86M |
| Capital Expenditures | n/a |
| Free Cash Flow | -32.86M |
| FCF Per Share | -$0.48 |
Full Cash Flow StatementMargins
| Gross Margin | -87.37% |
| Operating Margin | -254.05% |
| Pretax Margin | -466.09% |
| Profit Margin | n/a |
| EBITDA Margin | -253.74% |
| EBIT Margin | -254.05% |
| FCF Margin | n/a |
Dividends & Yields
Opus Genetics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -99.64% |
| Shareholder Yield | -99.64% |
| Earnings Yield | -43.38% |
| FCF Yield | -20.90% |
Analyst Forecast
The average price target for Opus Genetics is $7.17, which is 215.86% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $7.17 |
| Price Target Difference | 215.86% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 46.16% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Opus Genetics has an Altman Z-Score of -8.45 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -8.45 |
| Piotroski F-Score | 3 |
